Indivumed said today it will add proteomic and phosphoproteomic data to its IndivuType multi-omics cancer database through a collaboration with Biognosys whose value was not disclosed.
The collaboration is intended to enhance the IndivuType database by adding proteome-level data from thousands of samples using Biognosys’ proteomics technology, with the goal of enabling discoveries in cancer biology.
Samples collected by Indivumed will be analyzed with Biognosys’ solutions intended for highly multiplexed protein quantification, the companies said. Biognosys says its next-gen proteomics solutions are applicable in all species across a wide range of sample types, including tissue samples and body fluids for biomarker discovery and mechanism of action studies.
IndivuType is designed to analyze multiple omics layers—including genomics, transcriptomics, proteomics, phosphoproteomics and immunophenotyping—in combination with clinical and outcome data. IndivuType is designed to support the identification and validation of new molecular drug targets and biomarkers, patient stratification and cohort design for clinical trials, as well as multiple molecular aspects in basic and clinical research.
“Proteomics and phosphoproteomics play a crucial role in understanding cancer biology and adding Biognosys’ technology to the IndivuType multi-omics profile will enable relevant discoveries in our collaborations with pharma and biotech,” Indivumed CEO and founder Hartmut Juhl, M.D., Ph.D., said in a statement.
Biognosys is a developer of next-generation mass spectrometry-based proteomics technologies (HRM) designed to achieve unprecedented sensitivity and depth with high reproducibility from low microgram amounts of protein. According to Biognosys, its HRM technology enables profiling of protein expression and phosphorylation in large sample cohorts, with thousands of proteins capable of being quantified simultaneously in a single measurement, through the combination of high-resolution mass spectrometry and a novel parallel signal processing approach.
“With the development of the parallel acquisition based next-generation technology, proteomics has become both, more sensitive and higher throughput. This has been the basis for our partnership,” Oliver Rinner, CEO and founder of Biognosys, said of his company’s partnership with Individumed. “We are convinced that large scale proteomics and phosphoproteomics data from well characterized sample cohorts will add a highly relevant new dimension to quantitative biology, and specifically to cancer biology.”